Premium
PROMISING CLINICAL DATA FROM DOSE ESCALATION IN A PHASE IB/II ONGOING STUDY OF MOSUNETUZUMAB WITH POLATUZUMAB VEDOTIN FOR RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMA
Author(s) -
Diefenbach C,
Budde E,
Chavez J,
Lossos I. S,
Mehta A,
Dorritie K,
Kamdar M,
Negricea R,
Pham S,
Hristopoulos M,
Huw Ling-Y,
Hear C. O,
Oki Y,
To I,
Ghosh N
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.154_2880
Subject(s) - medicine , refractory (planetary science) , lymphoma , gastroenterology , brentuximab vedotin , follicular lymphoma , antibody drug conjugate , diffuse large b cell lymphoma , oncology , antibody , immunology , hodgkin lymphoma , monoclonal antibody , astrobiology , physics